Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nexalin Technology (NXL) EBT (2022 - 2025)

Historic EBT for Nexalin Technology (NXL) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • Nexalin Technology's EBT rose 702.92% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.7 million, marking a year-over-year decrease of 5610.2%. This contributed to the annual value of -$7.6 million for FY2024, which is 6374.51% down from last year.
  • Latest data reveals that Nexalin Technology reported EBT of -$2.3 million as of Q3 2025, which was up 702.92% from -$1.6 million recorded in Q2 2025.
  • Nexalin Technology's 5-year EBT high stood at -$303646.0 for Q3 2022, and its period low was -$2.8 million during Q4 2024.
  • Its 4-year average for EBT is -$1.3 million, with a median of -$1.0 million in 2024.
  • In the last 5 years, Nexalin Technology's EBT tumbled by 65653.52% in 2023 and then soared by 702.92% in 2025.
  • Nexalin Technology's EBT (Quarter) stood at -$733113.0 in 2022, then dropped by 6.49% to -$780669.0 in 2023, then crashed by 262.95% to -$2.8 million in 2024, then grew by 19.66% to -$2.3 million in 2025.
  • Its EBT stands at -$2.3 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$2.0 million for Q1 2025.